What is the best fit? Anti-CD38-VRd quads or anti-CD38-KRd quads as a new standard of care in NDMM

Speaker(s)

• 

  Thomas Martin, MD

  Clinical Professor of Medicine
  Department of Hematology, University of California at San Francisco, San Francisco, CA, USA
  San Francisco, United States
• 

  Lisa B. Leypoldt, MD (she/her/hers)

  Clinician Scientist/ Research Fellow
  University Medical Center Hamburg-Eppendorf, Germany / Dana-Farber Cancer Institute, Boston, MA, USA
  Hamburg, Germany